Posted by Michael Wonder on 14 Mar 2022
Incyte announces U.S. FDA has extended the supplemental new drug application review period for ruxolitinib cream (Opzelura) for the treatment of vitiligo
14 March 2022 - Incyte announced today that the U.S. FDA has extended the review period for the supplemental new drug application for ruxolitinib cream (Opzelura) for the treatment of vitiligo.
The Prescription Drug User Fee Act action date has been extended by three months to 18 July 2022.
